Recurrent, previously treated, locally advanced or metastatic NSCLC (non small cell lung cancer)
Showing 1 - 25 of >10,000
NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- MK-2870
- +2 more
- (no location specified)
Oct 3, 2023
NSCLC Trial (Sutetinib Maleate Capsule)
Not yet recruiting
- Non-small Cell Lung Cancer
- Sutetinib Maleate Capsule
- (no location specified)
Aug 18, 2023
NSCLC Trial (Amivantamab, Lazertinib, Doxycycline)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Amivantamab
- +6 more
- (no location specified)
Nov 7, 2023
NSCLC, NSCLC Trial in Guangzhou (Apatinib + Fluzoparib, Apatinib + Fluzoparib + Adebrelimab)
Not yet recruiting
- NSCLC
- Non-small Cell Lung Cancer
- Apatinib + Fluzoparib
- Apatinib + Fluzoparib + Adebrelimab
-
Guangzhou, Guangdong, ChinaSun Yat-Sen University Cancer Center
Jun 27, 2023
NSCLC Trial in Guangzhou (BL-M07D1)
Not yet recruiting
- Non-small Cell Lung Cancer
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Nov 1, 2023
KRAS P.G12C, Non Small Cell Lung Cancer Trial in France (Sotorasib 120Mg Tab)
Recruiting
- KRAS P.G12C
- Non Small Cell Lung Cancer
- Sotorasib 120Mg Tab
-
Lyon, France
- +3 more
Dec 16, 2022
Locally Advanced or Metastatic NSCLC Trial (Utidelone Injection, Docetaxel Injection)
Not yet recruiting
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Utidelone Injection
- Docetaxel Injection
- (no location specified)
Dec 30, 2022
NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)
Not yet recruiting
- Non-Small Cell Lung Cancer
- +2 more
-
Fairfax, VirginiaNEXT Virginia
Sep 18, 2023
Advanced NSCLC Trial (Trilaciclib+Envafolimab+Docetaxel, Envafolimab+Docetaxel, Docetaxel)
Not yet recruiting
- Advanced Non-Small Cell Lung Cancer
- (no location specified)
Jun 16, 2023
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Trial in Canton (TAS6417)
Recruiting
- Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
-
Canton, OhioGabrail Cancer and Research Center
Jul 25, 2023
Non Small Cell Lung Cancer, Locally Advanced, Radiotherapy Trial in Wuhan (CTV omitted or delineated)
Not yet recruiting
- Non Small Cell Lung Cancer
- +3 more
- CTV omitted or delineated
-
Wuhan, Hubei, ChinaHubei Cancer Hospital
Sep 1, 2023
NSCLC (NSCLC) Trial (Osimertinib, Amivantamab)
Not yet recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- (no location specified)
Mar 24, 2023
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Seattle
Not yet recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +2 more
- Atezolizumab
- +6 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 6, 2023
Carcinoma, Squamous Cell of Head and Neck, NSCLC, Ovarian Tumors Trial (disitamab vedotin)
Not yet recruiting
- Carcinoma, Squamous Cell of Head and Neck
- +3 more
- disitamab vedotin
- (no location specified)
Aug 15, 2023
Non-Small-Cell Lung Cancer Trial in Guangzhou (PLB1004)
Recruiting
- Non-Small-Cell Lung Cancer
-
Guangzhou, Guangdong, ChinaGuangdong General Hospital
Aug 25, 2023
Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III Trial in Tampa (Genomically
Recruiting
- Nonsmall Cell Lung Cancer
- +3 more
- Genomically Guided Radiation Therapy (RT)
-
Tampa, FloridaMoffitt Cancer Center
May 23, 2023
NSCLC (Non-small-cell Lung Cancer) Trial in Changchun (Sintilimab, IBI310)
Recruiting
- NSCLC (Non-small-cell Lung Cancer)
-
Changchun, Jilin, ChinaThe First Hospital of Jilin University
Sep 21, 2022
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Trial in
Recruiting
- Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
-
Canton, OhioGabrail Cancer and Research Center
Jul 21, 2023
Lazertinib as the 2nd-Line Treatment in EGFR Mutation+ NSCLC
Completed
- Non-small Cell Lung Cancer
- Lazertinib
- Platinum-based Chemotherapy
- (no location specified)
May 8, 2023
NSCLC Trial in Busan (GDC-6036, Pembrolizumab)
Recruiting
- Non-Small Cell Lung Cancer
-
Busan, Korea, Republic ofPusan National University Hospital
Apr 3, 2023
Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48 Trial in Guanzhou (RC48+Tislelizumab+carboplatin,
Not yet recruiting
- Non Small Cell Lung Cancer
- +3 more
- RC48+Tislelizumab+carboplatin
- +2 more
-
Guanzhou, ChinaSunYat-senU
May 5, 2023